Literature DB >> 27216012

Diabetes mellitus and pre-diabetes are frequently undiagnosed and underreported in patients referred for pancreatic surgery. A prospective observational study.

Geert Roeyen1, Miet Jansen2, Thiery Chapelle2, Bart Bracke2, Vera Hartman2, Dirk Ysebaert2, Christophe De Block3.   

Abstract

OBJECTIVE: Previous reports on the prevalence of diabetes in pancreatic cancer and chronic pancreatitis patients are based on inconsistent and equivocal criteria. The objective of this study is to prospectively assess with conclusive methods the preoperative glycaemic status of patients undergoing pancreatic surgery. We hypothesise that most of those patients are unaware of these disturbances in glycaemic status and that the prevalence is underestimated.
METHODS: During the last 2 years, patients referred for pancreatic surgery and without history of diabetes underwent a prospective preoperative screening with an oral glucose tolerance test (OGTT) and determination of the glycated haemoglobin level (HbA1c). The American Diabetes Association's criteria for diabetes and pre-diabetes were used. Beta-cell function and insulin sensitivity were calculated using HOMA2 indices. Impact on surgical policy has been scored.
RESULTS: 99 patients were screened, 25 had a history of diabetes. The other 74 underwent an OGTT and HbA1c determination. Only 29.7% (22/74) had a normal glucose metabolism, while 8.1% (6/74) had impaired fasting glucose, 21.6% (16/74) had impaired glucose tolerance, 6.7% (5/74) had a combination of both, and 33.8% (25/74) had undiagnosed diabetes. In 15.2% (15/99) of the patients, this preoperative assessment had an impact on surgical policy.
CONCLUSIONS: 77.7% of patients referred for pancreatic surgery had some degree of (pre-)diabetes. In 70.3% of patients without a history of diabetes, these disturbances in glucose metabolism are a new finding. Physicians involved in pancreatic surgery should be aware of the frequently undiagnosed (pre-)diabetes and actively check for it. This prevalence is underestimated.
Copyright © 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Chronic pancreatitis; Endocrine function; Pancreas; Pancreatogenic diabetes; Prediabetes

Mesh:

Substances:

Year:  2016        PMID: 27216012     DOI: 10.1016/j.pan.2016.04.032

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  3 in total

Review 1.  Nutritional and Metabolic Derangements in Pancreatic Cancer and Pancreatic Resection.

Authors:  Taylor M Gilliland; Nicole Villafane-Ferriol; Kevin P Shah; Rohan M Shah; Hop S Tran Cao; Nader N Massarweh; Eric J Silberfein; Eugene A Choi; Cary Hsu; Amy L McElhany; Omar Barakat; William Fisher; George Van Buren
Journal:  Nutrients       Date:  2017-03-07       Impact factor: 5.717

2.  Retrospective cohort of pancreatic and Vater ampullary adenocarcinoma from a reference center in Mexico.

Authors:  Jorge Sánchez-García; Fernando Candanedo-González; Anna Karen Félix-Félix; Damián Sánchez-Ramírez; Rafael Medrano-Guzmán; Miguel Quintana-Quintana; Yair Benjamín Baas-Cabrera; Eugenia Flores-Figueroa
Journal:  Ann Med Surg (Lond)       Date:  2018-04-11

3.  Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study.

Authors:  Dominik J Ose; Richard Viskochil; Andreana N Holowatyj; Mikaela Larson; Dalton Wilson; William A Dunson; Vikrant G Deshmukh; J Ryan Butcher; Belinda R Taylor; Kim Svoboda; Jennifer Leiser; Benjamin Tingey; Benjamin Haaland; David W Wetter; Simon J Fisher; Mia Hashibe; Cornelia M Ulrich
Journal:  J Natl Compr Canc Netw       Date:  2021-03-10       Impact factor: 11.908

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.